Table 1.
Characteristics and access to liver specialty care at baseline of participants with HIV and HCV coinfection
| Access to liver specialty care
|
|||
|---|---|---|---|
| Baseline characteristics | With access, n = 50 | Without access, n = 181 | P |
| Age, M (SD) | 45.0 (6.3) | 43.5 (7.0) | .14 |
| Female gender, n (%) | 14 (28) | 52 (29) | .92 |
| Race or ethnicity, n (%) | .33 | ||
| Black | 17 (34) | 70 (39) | |
| White | 21 (42) | 56 (31) | |
| Other | 12 (24) | 55 (30) | |
| Substance abuse treatment, n (%) | 29 (58) | 87 (48) | .21 |
| Current ART receipta, n (%) | 40 (80) | 102 (56) | .002 |
| Baseline CD4 cell count (cells/mm3), M (SD) | 423 (253) | 408 (260) | .86 |
| Liver disease complicationsb,c, n (%) | 9 (18) | 6 (3) | .0002 |
| Elevated ALT (>40 IU/L), n (%) | 36 (75) | 120 (68) | .39 |
| Depressive symptomsd, n (%) | 29 (58) | 110 (61) | .72 |
| Ever had psychiatric treatment, n (%) | 35 (70) | 119 (66) | .57 |
| Injection drug useb, n (%) | 7 (14) | 45 (25) | .10 |
| 30-day alcohol abstinence, n (%) | 38 (76) | 107 (59) | .03 |
| Alcohol dependenceb,e, n (%) | 2 (4) | 21 (12) | .11 |
a
Highly active antiretroviral therapy.
b
In the past 6 months.
c
Any liver complications refer to jaundice, ascites, hepatic encephalopathy, esophageal varices, or gastrointestinal bleeding.
d
Using the CES-D, where ≥21 denotes depressive symptoms in chronic diseases.
e
Alcohol dependence as defined by the CIDI short form.